Molecular monitoring of bcr-abl transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 5, 2013, Pages 735-740

  Arpinati, Mario ^a   Tolomelli, Giulia ^a   Bochicchio, Maria Teresa ^a   Castagnetti, Fausto ^a   Amabile, Marilina ^a   Bandini, Giuseppe ^a   Bonifazi, Francesca ^a   Stanzani, Marta ^a   Rosti, Gianantonio ^a   Martinelli, Giovanni ^a   Baccarani, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Allogeneic hematopoietic stem cell transplantation (HSCT); BCR ABL; Chronic myeloid leukemia (CML); Minimal residual disease (MRD)

Indexed keywords

BCR ABL PROTEIN;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD; BONE MARROW; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TREATMENT INDICATION;

ADULT; FEMALE; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; RNA, MESSENGER; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84876299543     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.01.007     Document Type: Article

References (41)

1. van Rhee F., Lin F., Cullis J.O., et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994, 83:3377-3383.
2. Goldman J.M., Majhail N.S., Klein J.P., et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol 2010, 28:1888-1895.
3. Martinelli G., Montefusco V., Testoni N., et al. Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation. Haematologica 2000, 85:653-658.
4. Hughes T., Deininger M., Hochhaus A., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108:28-37.
5. Hochhaus A., Lin F., Reiter A., et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 1996, 87:1549-1555.
6. Román J., Alvarez M.A., Torres A. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation. Haematologica 2000, 85:1072-1082.
7. Emig M., Saussele S., Wittor H., et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999, 13:1825-1832.
8. Saglio G., Baccarani M. First-line therapy for chronic myeloid leukemia: new horizons and an update. Clin Lymph Myel Leuk 2010, 10:169-176.
9. Kaeda J., O'Shea D., Szydlo R.M., et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood 2006, 107:4171-4176.
10. Cummins M., Cwynarski K., Marktel S., et al. Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT). Bone Marrow Transplant 2005, 36:1065-1069.
11. Deol A., Lum L.G. Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev 2010, 36:528-538.
12. Wright M.P., Shepherd J.D., Barnett M.J., et al. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010, 16:639-646.
13. Conchon M., Sanabani S.S., Bendit I., et al. The use of imatinib mesylate as a lifesaving treatment of chronic myeloid leukemia relapse after bone marrow transplantation. J Transplant 2009, 2009:357093. Epub 2009 Oct 22. 10.1155/2009/357093.
14. Palandri F., Amabile M., Rosti G., et al. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. Bone Marrow Transplant 2007, 39:189-191.
15. Gratwohl A., Hermans J., Niederwieser D., et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1993, 12:509-516.
16. Bonifazi F., Bandini G., Rondelli D., et al. Reduced incidence of GVHD without increase in relapse with low-dose rabbit ATG in the preparative regimen for unrelated bone marrow transplants in CML. Bone Marrow Transplant 2003, 32:237-242.
17. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974, 18:295-304.
18. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
19. Martinelli G., Iacobucci I., Rosti G., et al. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. Ann Oncol 2006, 17:495-502.
20. Gabert J., Beillard E., van der Velden V.H., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia 2003, 17:2318-2357.
21. Ballestrero A., Cirmena G., Dominietto A., et al. Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients. Int J Lab Hematol 2010, 32:387-391.
22. Kitzis A., Brizard F., Dascalescu C., et al. Persistence of transcriptionally silent BCR-ABL rearrangements in chronic myeloid leukemia patients in sustained complete cytogenetic remission. Leuk Lymph 2001, 42:933-944.
23. Román J., Serrano J., Jiménez A., et al. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia. Haematologica 2000, 85:173-180.
24. Asnafi V., Rubio M.T., Delabesse E., et al. Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2006, 20:793-799.
25. Geng S.X., DU X., Weng J.Y., et al. Significance of quantitative detection of bcr-abl mRNA in chronic myeloid leukemia patients after allogeneic hematopoietic stem cell transplant. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007, 15:993-997. [In Chinese].
26. Preudhomme C., Revillion F., Merlat A., et al. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay. Leukemia 1999, 13:957-964.
27. Miyamura K., Barrett A.J., Kodera Y., et al. Minimal residual disease after bone marrow transplantation for chronic myelogenous leukemia and implications for graft-versus-leukemia effect: a review of recent results. Bone Marrow Transplant 1994, 14:201-209.
28. Santini V., Zoccolante A., Bosi A., et al. Detection of bcr/abl transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation. Haematologica 1996, 81:201-207.
29. Otazú I.B., Tavares Rde C., Hassan R., et al. Estimations of BCR-ABL/ABL transcripts by quantitative PCR in chronic myeloid leukaemia after allogeneic bone marrow transplantation and donor lymphocyte infusion. Leuk Res 2002, 26:129-141.
30. van Rhee F., Lin F., Cross N.C., et al. Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia. Bone Marrow Transplant 1994, 14:609-612.
31. Bose S., Deininger M., Gora-Tybor J., et al. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998, 92:3362-3367.
32. Chomel J.C., Brizard F., Veinstein A., et al. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation. Blood 2000, 95:404-408.
33. Quintarelli C., Dotti G., Hasan S.T., et al. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood 2011, 117:3353-3362.
34. Zander A.R., Kröger N., Schleuning M., et al. ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). Bone Marrow Transplant 2003, 32:355-361.
35. Schleuning M., Günther W., Tischer J., et al. Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML. Bone Marrow Transplant 2003, 32:243-250.
36. Kröger N., Zabelina T., Krüger W., et al. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant 2002, 29:683-689.
37. Huang X.J., Xu L.P., Liu K.Y., et al. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia. Biol Blood Marrow Transplant 2011, 17:649-656.
38. Kim Y.J., Kim D.W., Lee S., et al. Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial. Bone Marrow Transplant 2004, 33:535-542.
39. Olavarria E., Craddock C., Dazzi F., et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 2002, 99:3861-3862.
40. Wassmann B., Klein S.A., Scheuring U., et al. Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation. Bone Marrow Transplant 2001, 28:721-724.
41. McCann S.R., Gately K., Conneally E., et al. Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML. Blood 2003, 101:1200-1201. [Erratum in Blood 2003 Mar 1;101:1683.].